On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug will be used in Peptide Receptor Radionuclide Therapy (PRRT), which is a form of targeted treatment. LUTATHERA®(lutetium Lu 177 dotatate) is indicated for adult patients with somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors. Read more